若生智能
Drug Database
IN

influenza vaccine (CSL425 / Panvax, H1N1)

✓ Approved

CSL Limited · 疫苗 · 疫苗

什么是 influenza vaccine？

influenza vaccine 是一种疫苗，由CSL Limited研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名CSL425, Panvax, H1N1
公司CSL Limited
药物类别疫苗, 大分子
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, CSL Limited

相关研究文献

PubMedInfluenza and other respiratory viruses2026-08-06

Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation During the 2024/25 Season in Northern Ireland, UK.

Bucholc Magda M, Murphy Siobhán S, O'Doherty Mark G MG, Wilton Suzanne S et al.

Seasonal influenza causes substantial morbidity and hospitalisation each year. We estimated influenza vaccine effectiveness (VE) against laboratory-confirmed influenza-associated hospitalisation among patients in Northern Ireland (NI) during the 2024/25 influenza season. We used a test-negative design to estimate VE against hospitalisation. Influenza-positive cases and test-negative controls were identified through the national laboratory surveillance system and linked to hospital admission and vaccination records. VE was estimated by influenza type/subtype, age group, sex, vaccine type and time since vaccination. Among 15,133 hospitalised patients, 2024 (13.4%) tested positive for influenza. Among the 2024 patients admitted with laboratory-confirmed influenza, the vast majority tested positive for influenza A (n = 1803; 89.1%), whereas 221 cases (10.9%) were influenza B. Subtyping of influenza A identified 606 A(H1) infections and 93 A(H3) infections; the remaining 1104 influenza A samples were not subtyped. VE against laboratory-confirmed influenza infection was 46.0% (95% CI: 39.7% to 51.8%), with higher VE in children aged 2-17 years (60.8%; 95% CI: 48.3% to 70.5%) than in adults aged 18-64 years (40.5%; 95% CI: 24.9% to 53.2%) and ≥ 65 years (42.3%; 95% CI: 33.2% to 50.1%). VE against influenza A across all ages was 41.4% (95% CI: 34.2% to 47.9%). Vaccination reduced the odds of hospitalisation due to influenza A(H1) by 44.3% (95% CI: 33.2% to 53.7%) and A(H3) by 49.9% (95% CI: 20.3% to 69.3%). VE against influenza B was higher at 76.4% (95% CI: 64.9% to 84.7%). For influenza A, VE was highest 2-8 weeks after vaccination at 51.9% (95% CI: 42.1% to 60.1%) and declined with time since vaccination to 44.6% (95% CI: 35.6% to 52.5%) at 9-16 weeks and 41.4% (95% CI: 15.4% to 60.1%) at ≥ 16 weeks. VE against influenza B remained high throughout the season. No statistically significant differences in VE by vaccine type were found. Influenza vaccination reduced the risk of hospitalisation with laboratory-confirmed influenza during the 2024/25 season, offering meaningful protection at individual and population levels, with the greatest benefit observed in children.

PMID 42560010
阅读全文 →
PubMedThe International journal of pharmacy practice2026-08-06

Expanding the role of pharmacists as vaccinators in New Zealand: a retrospective analysis of influenza vaccination trends following policy change.

Larson Anna A, Mitrovich Rachel R, Musse Isabel I, Lansdale Aimee J AJ et al.

Pharmacy-based influenza vaccination became part of New Zealand's public vaccination programme in 2017, eliminating out-of-pocket costs to consumers. This study evaluated trends in pharmacy-based influenza vaccination among adults aged ≥65 in New Zealand following the 2017 funding policy change, with the aim of examining whether the availability of government-funded influenza vaccination increased pharmacy-based vaccination in this population. Data on influenza vaccinations administered between 2015 and 2021 to adults ≥65 were provided by the New Zealand Ministry of Health from the National Immunisation Register. Descriptive analyses were employed to assess the absolute number and percentage of vaccinations given by each provider type from 2015 through 2021 to document trends after the public funding policy change and in the early years of the COVID-19 pandemic. The total number of influenza vaccinations administered increased from 322 161 in 2015 to 525 769 in 2021. After public funding for influenza vaccination began in pharmacies, annual physician- and nurse-administered vaccinations ranged from 401 840 to 426 005 and 12 590 to 19 586, respectively, between 2018 and 2021, while pharmacist-administered vaccinations steadily increased from 16 042 to 96 343. The percentage of influenza vaccinations administered by pharmacists grew from nearly 0% in 2015 to 3.7% in 2018 and 18.3% in 2021. Research findings suggest that public funding for pharmacist-administered influenza vaccinations contributed to expanding overall influenza vaccine access in New Zealand among adults ≥65. In addition, the increase in pharmacist-delivered vaccinations did not negatively impact vaccinations administered by traditional providers, further demonstrating the value and growing role of pharmacies in advancing national immunization efforts.

PMID 42560331
阅读全文 →
PubMedMicrobiology spectrum2026-08-06

Detection and characterization of antiviral-resistant viruses during the influenza season of 2024-25.

Patel Mira C MC, Nguyen Ha T HT, Pascua Philippe Noriel Q PNQ, Lopez-Esteva Mercedes M et al.

During the high severity season of 2024-25, CDC with public health partners sequenced and analyzed genomes of >10,000 influenza viruses for antiviral resistance markers. Available sequence-flagged and representative viruses were tested with antivirals using in vitro assays. In the US, three oseltamivir-resistant A(H3N2) viruses had treatment-emergent neuraminidase (NA) mutations, either E119V or R292K. Oseltamivir-resistant A(H1N1)pdm09 viruses with NA-H275Y were detected in 15 states, albeit at a low frequency (0.53%). They belonged to several phylogenetic groups, with hemagglutinin (HA) subclade D.3.1 combined with either NA subclade D.1 or D.2 being most common. Based on shared sequence data, nearly all H275Y viruses from Australia, Canada, and Chile also belonged to these HA and NA subclades. Conversely, most H275Y viruses (68/81) from China belonged to HA subclade C.1.9 and NA subclade D and shared the permissive mutation R257K. Influenza polymerase acidic (PA) mutations conferring 4- to 92-fold decreased baloxavir susceptibility were detected in nine influenza A viruses. Viruses with PA-I38T showed mild attenuation of replicative fitness in three cell lines. Based on available data, NA-H275Y and PA-I38T viruses were collected from patients with no exposure to antivirals. Baseline susceptibility to all US-approved influenza antivirals remained largely unchanged compared to previous seasons. All swine-origin viruses detected in the US had adamantane resistance-conferring marker, M2-S31N, but remained susceptible to other approved antivirals. Monitoring antiviral susceptibility has substantially improved with increased sequencing capacities and bioinformatic support at public health laboratories. Information gained through influenza surveillance has been used to guide recommendations on antiviral use. Circulation of influenza viruses with reduced susceptibility to antivirals can diminish the usefulness of medications prescribed for influenza. This study informs on the prevalence of drug-resistant influenza viruses in the US during the high severity season of 2024-25. It provides information on susceptibility profile to all approved antiviral medications and on replicative fitness of representative drug-resistant viruses. Most drug-resistant viruses were collected from patients who were not exposed to antivirals indicating their ability to transmit from human to human. Whole-genome sequence (WGS)-based analysis is the cornerstone for surveillance, and numerous laboratories have been utilizing this approach. However, CDC laboratory is the only laboratory in the US conducting phenotypic testing of circulating viruses needed to confirm the outcomes of sequence-based analysis and to identify new molecular markers of resistance. Data gathered through virologic surveillance give much-needed information on drug susceptibility of influenza viruses which are used to guide recommendations on antiviral use.

PMID 42560041
阅读全文 →
PubMedBMJ open2026-08-06

Epidemiology, trends and determinants of influenza and SARS-CoV-2 positivity among severe acute respiratory infection patients in Cambodia, 2020-2024: a hospital-based retrospective cross-sectional surveillance data analysis.

Pong Khemrin K, Long Hayputhik H, Mom Sokly S, Ung Sophanith S et al.

To describe the epidemiological pattern, temporal trends of influenza and SARS-CoV-2, and determinants of severe acute respiratory infection (SARI)-confirmed positivity among patients hospitalised with SARI in Cambodia. A hospital-based retrospective cross-sectional surveillance data analysis using national sentinel SARI surveillance data collected from 2020 to 2024. Nine SARI sentinel hospitals are located across Cambodia. A total of 16 739 hospitalised patients who met the SARI case definition. SARI-confirmed positivity defines all SARI cases with laboratory-confirmed influenza or SARS-CoV-2 infections as the main outcome measure. Descriptive and bivariate analyses were performed, followed by multivariate logistic regression to identify factors associated with SARI-confirmed positivity. Among 16 739 SARI cases, median age in years was 16 (IQR=59), with 54.6% being male; 13.5% were laboratory-confirmed for influenza or SARS-CoV-2. High mortality rate in 2021. A(H3N2) dominated in 2020, followed by widespread SARS-CoV-2 circulation in 2021. In 2022, SARS-CoV-2 co-circulated with A(H3N2) and influenza B (Victoria). A(H1N1)pdm became the predominant strain in 2023 as SARS-CoV-2 and A(H3N2) declined. In 2024, A(H3N2) again led circulation, with B(Victoria) and SARS-CoV-2 also detected. Sporadic A(H5N1) cases began appearing in late 2023. Multivariable analysis indicated higher odds of SARI-confirmed positivity among children aged 5-14 years (adjusted OR (aOR)=1.85; 95% CI 1.47 to 2.31) and adults 50-64 years (aOR=1.36; 95% CI 1.15 to 1.60) compared with adults 25-49 years, during the rainy season (aOR=2.09; 95% CI 1.89 to 2.32) and among patients in Phnom Penh compared with other regions (p<0.001). Influenza detection markedly increased from 2022 to 2024 following the decline observed during the COVID-19 pandemic. These results indicate that there was an increase in SARI trends over the periods and the changing influenza subtypes circulating each year, along with a high mortality rate during the Delta variant COVID-19 pandemic in Cambodia. Age, region, year and season were significant factors associated with SARI-confirmed positivity. Targeted interventions and preventive measures should be prioritised for specific high-risk groups.

PMID 42556831
阅读全文 →
PubMedMicrobiology spectrum2026-08-06

Neutralizing and protective monoclonal antibodies identify antigenic sites in influenza H7 hemagglutinin and select for amino acid substitutions rarely observed at the global level.

Parra Gabriel I GI, Odin Marcus M, Tohma Kentaro K, Schmeisser Falko F et al.

Avian influenza viruses of the H7 subtype infect a variety of avian as well as mammalian species, and a better understanding of H7 virus antigenicity and immunogenicity is vital to the development of effective countermeasures for a potential H7 pandemic threat. We have developed a diverse panel of murine monoclonal antibodies (mAbs) to the H7 hemagglutinin (HA) and characterized these mAbs for the HA epitope(s) that they bind, their neutralizing activity in vitro against several strains of H7, and their ability to provide protection against virus challenge in vivo. The majority of the isolated mAbs recognized antigenic sites A and B on the globular head of the influenza HA, but mAbs were also isolated to non-canonical sites on HA. Escape viruses generated against the mAbs were used to further define the antigenic sites on the H7 HA, and notably, we find that most amino acid substitutions identified in these escape viruses are rare at the global level. Finally, we used a polyclonal antibody generated by virus infection to assess whether antibody binding and neutralization were impacted by individual amino acid substitutions in the HA of escape viruses generated by the mAbs. The results showed that all of the escape viruses, each of which carried a single amino acid substitution, were still effectively neutralized by polyclonal antibodies, suggesting that the antibody response to H7 infection was broad and redundant.IMPORTANCEInfluenza H7 viruses infect a variety of avian and mammalian species, and present a potential threat to human health. We used a panel of murine monoclonal antibodies (mAbs) to facilitate the identification of important protective epitopes on the H7 hemagglutinin (HA). While most of the antibodies bind to antigenic sites A and B on the H7 HA that correspond to well-characterized cognate sites on influenza H3, some antibodies appear to recognize new epitopes in HA distinct from those known antigenic sites. We also identified amino acid substitutions in escape viruses selected by these mAbs and evaluated their impact in the context of polyclonal responses and natural H7 virus evolution over a >60-year period. Taken together, the results add to our understanding of influenza H7 virus antigenicity and immunogenicity, and may have positive implications for successful H7 vaccine development.

PMID 42560073
阅读全文 →
PubMedChina CDC weekly2026-08-06

First Human Infection with Influenza A(H1N2)v Virus - Yunnan Province, China, 2026.

Chen Lihua L, Chen Yaoyao Y, Han Xiaoyu X, Ni Ruize R et al.

Human infections with influenza A(H1N2)v viruses of swine origin have been sporadically reported in several countries, usually following direct or indirect exposure to pigs or contaminated environments. However, sustained human-to-human transmission has not yet been documented. This report describes the first laboratory-confirmed human infection with the influenza A(H1N2)v virus in China. Whole-genome sequencing showed that all eight gene segments were closely related to influenza viruses of swine origin circulating in China. No secondary human cases were identified among the close contacts, and no evidence of sustained human-to-human transmission was detected. This highlights the importance of routine influenza-like illness surveillance, timely whole-genome sequencing, and systematic investigation of unusual influenza A infections. Strengthened surveillance at the human-animal interface and cross-sector collaboration under the One Health framework are essential for early detection and risk assessment of variant influenza viruses.

PMID 42558201
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多influenza vaccine